CC BY-NC-ND 4.0 · Neurology International Open 2018; 02(01): E56-E59
DOI: 10.1055/s-0043-125342
Review
Eigentümer und Copyright ©Georg Thieme Verlag KG 2018

Escalation Strategies in the Treatment of Refractory Myasthenia Gravis

Sarah Hoffmann
1  Klinik für Neurologie, Charité – Universitätsmedizin Berlin
2  NeuroCure Clinical Research Centre (NCRC), Charité – Universitätsmedizin Berlin
,
Andreas Meisel
1  Klinik für Neurologie, Charité – Universitätsmedizin Berlin
2  NeuroCure Clinical Research Centre (NCRC), Charité – Universitätsmedizin Berlin
› Author Affiliations
Further Information

Publication History

Publication Date:
21 February 2018 (online)

Abstract

Among all patients with myasthenia gravis (MG), 10 to 15% are considered to be refractory to (expanded) standard treatments. Current international consensus guidelines for the management of myasthenia gravis recommend referral of refractory MG patients to centers with expertise in the treatment of MG and chronic intravenous immunoglobulin therapy or plasmapheresis. Here we briefly summarize current approaches to overcome refractory myasthenia gravis.